June 2021 Report on Global Psychedelic Drugs Market Size, Share, Value, and Competitive Landscape 2020

(Heraldkeepers via Comtex)

The Covid-19 pandemic has restricted the movement of people, confining them in their homes, caused severe trauma and stress in the form of sadness and loneliness and has affected the mental health of individuals. As a result, in many countries, people are facing medical conditions like depression and anxiety. The psychedelic drugs market with major potential for treatment of mental illnesses is likely to see more demand and hence likely to attract major investments in the near future.

GET FREE SAMPLE PDF : https://www.wiseguyreports.com/sample-request/7124392-global-psychedelic-drugs-market-2021-edition-analysis-by

Global Psychedelic Drugs Market was valued at USD 3.8 billion in the year 2020. The Psychedelic Drugs market is growing rapidly due to the increasing prevalence of depression and other mental disorders worldwide. The need for handling environmental stress and enhanced and better quality of lifestyle is acting as a driver for the Psychedelic Drugs market. The treatment for psychedelic drugs dependency is expected to boost psychedelic market growth.

ALSO READ :http://www.marketwatch.com/story/global-professional-tableware-market-size-share-value-and-competitive-landscape-2021-2026-2021-05-10

In addition, rising research and development activities in psychedelic therapeutics categories across the world have supported industrial development significantly. Companies are aggressively investing in R&D activities to develop novel psychedelic treatment molecules with minimal side effects associated with these products. This has further resulted in a strong platform for the further growth of the psychedelic drug industry during the forecast period.

ALSO READ :http://www.marketwatch.com/story/global-digital-oilfield-market-size-share-value-and-competitive-landscape-2020-2021-05-11

The North America region dominates the psychedelic drugs market. In North America, growing awareness of mental health disorders such as depression and stress is expected to boost the psychedelic drug market growth. Social elements such as economic stress, the partition of family-oriented supporting structures, exacerbating environmental conditions are further estimated to accelerate market growth during forecast period.

ALSO READ :http://www.marketwatch.com/story/global-embedded-subscriber-identity-module-e-sim-professional-survey-market-size-share-value-and-competitive-landscape-2024-2021-05-11

Scope of the Report

? The report presents the analysis of Psychedelic Drugs Market for the historical period of 2016-2020 and the forecast period of 2021-2026.

? The report analyses Psychedelic Drugs Market by Route of Administration (Oral, Intranasal, Intravenous, Others)

? The report further assesses the Psychedelic Drugs Market by Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin, Others)

? The report further assesses the Psychedelic Drugs Market by Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

? The Global Psychedelic Drugs has been analysed By Region (North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, Italy, Spain, United Kingdom, China, Japan, India)

? The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions and Product Launch. Also, the attractiveness of the market has been presented By Region, By Route of Administration, By Drug and By Distribution Channel. Additionally, trends, drivers and challenges of the industry has been analysed in the report.

? The companies analysed in the report include Johnson & Johnson, Pfizer, AbbVie Inc., Jazz Pharmaceuticals, NUMINUS WELLNESS INC WS, COMPASS Pathways PLC, Mindset Pharma, Mydecine Innovations Group, TRYP Therapeutics Inc, MindMed and Cybin Inc.

Key Target Audience

? Pharmaceutical Companies

? Biotechnology Companies

? Research and Development (R&D) Companies

? Medical Research Laboratories

? Government and Research Organisations

TABLE OF CONTENTS

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global Psychedelic Drugs Market Product Outlook

4. Global Psychedelic Drugs Market: An Analysis

4.1 Market Size, By Value, Year 2016-2026

4.2 COVID-19 Impact on Psychedelic Drugs Market

5. Global Psychedelic Drugs Market Segmentation By Route of Administration (By Value)

5.1 Competitive Scenario of Global Psychedelic Drugs Market: By Route of Administration

5.2 Oraln Market Size and Forecast (2016-2026)

5.3 Intranasaln Market Size and Forecast (2016-2026)

5.4 Intravenousn Market Size and Forecast (2016-2026)

5.5 Othersn Market Size and Forecast (2016-2026)

6. Global Psychedelic Drugs Market Segmentation By Drug (By Value)

6.1 Competitive Scenario of Global Psychedelic Drugs Market: By Drug

6.2 Gamma-hydroxybutyraten Market Size and Forecast (2016-2026)

6.3 Ketaminen Market Size and Forecast (2016-2026)

6.4 Psilocybinn Market Size and Forecast (2016-2026)

6.5 MDMAn Market Size and Forecast (2016-2026)

6.6 Othersn Market Size and Forecast (2016-2026)

7. Global Psychedelic Drugs Market Segmentation By Distribution Channel (By Value)

7.1 Competitive Scenario of Global Psychedelic Drugs Market: By Distribution Channel

ALSO READ : http://www.marketwatch.com/story/global-phorp-sensors-market-outlook-industry-analysis-and-prospect-2021-2021-05-12

7.2 Hospitals Pharmacyn Market Size and Forecast (2016-2026)

7.3 Retail Pharmacyn Market Size and Forecast (2016-2026)

7.4 Online Pharmacyn Market Size and Forecast (2016-2026)

8. Global Psychedelic Drugs Market: Regional Analysis

8.1 Competitive Scenario of Global Psychedelic Drugs Market: By Region

9. North America Psychedelic Drugs Market: An Analysis (2016-2026)

9.1 North America Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value

9.2 North America Psychedelic Drugs Market n Prominent Companies

9.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)

9.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)

9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)

ALSO READ :http://www.marketwatch.com/story/global-measles-vaccine-marketsize-share-value-and-competitive-landscape-2020-2021-05-13

9.6 North America Psychedelic Drugs Market: Country Analysis

9.7 Market Opportunity Chart of North America Psychedelic Drugs Market – By Country, By Value (Year-2026)

9.8 Competitive Scenario of North America- By Country

9.9 United States Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value

9.10 United States Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.

9.11 Canada Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value

9.12 Canada Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.

10. Europe Psychedelic Drugs Market: An Analysis (2016-2026)

10.1 Europe Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value

10.2 Europe Psychedelic Drugs Market n Prominent Companies

10.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)

10.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)

10.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)

10.6 Europe Psychedelic Drugs Market: Country Analysis

10.7 Market Opportunity Chart of Europe Psychedelic Drugs Market – By Country, By Value (Year-2026)

10.8 Competitive Scenario of Europe- By Country

.

.

….. continued

CONTACT DETAILS :

[email protected]

+44 203 500 2763

+1 62 825 80070

971 0503084105

 

comtex tracking

COMTEX_388143671/2582/2021-06-11T10:33:07